Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Combination of GTI-2040 and capecitabine examined in renal cell carcinoma

Nov. 5, 2001

Next-generation oncolytic virus from Onyx selectively propagates in tumor cells

Nov. 5, 2001

Completion of rolling BLA submission for Erbitux

Nov. 5, 2001

Year-end completion of recruitment expected in renal cell carcinoma trial of Neovastat

Nov. 5, 2001

ChemGenex investigates molecular targets of Ceflatonin

Nov. 5, 2001

TBI-361, a new chemo- and radiosensitizing PARP inhibitor

Nov. 5, 2001

Novel apoptosis-inducing anticancer agent developed at NCI

Nov. 5, 2001

ISIS-3521-containing combinations effective, well tolerated in NSCLC according to phase I/II data

Nov. 5, 2001

Fatty acid-targeted taxane undergoing phase II testing for breast and prostate cancer

Nov. 5, 2001

Duke University initiates phase I telomerase immunotherapy trial for prostate cancer

Nov. 5, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...